Biomoda, Inc. Readies Products to Assist Insurer Reimbursement
Outsourcing Partner Speeds Entry Into Commercial Cancer Detection and Treatment Market
Albuquerque, N.M. – (Business Wire), June 30, 2004 - Biomoda, Inc. has contracted with JR Associates www.jrareimbursement.com to help advance Biomoda’s patented products, primarily involved with early detection and targeted treatment of specific cancers, potential for securing positive coverage, coding, and payment by Medicare and commercial insurers. Ultimately, these activities will assure patient access to Biomoda’s products and systems. JR Associates, Reseda, CA is prominent in the field of reimbursement strategies and has provided services to many major makers of medical products and systems. Reimbursement and coding are critical issues to medical reference laboratories, Biomoda’s anticipated primary market.
Biomoda, Inc., a development stage in-vitro diagnostics organization, is focused on research, development and commercialization of cancer diagnostics. The Company, exclusive worldwide licensee from the University of California of several patents developed for noninvasive early detection and treatment of lung cancer is in the process of registering additional patents in this area. The Company’s proprietary technologies provide minimally invasive and minimal impact approaches as cancer diagnostic products. Operating from its laboratory situated at Kirtland Air Force Base (Albuquerque, NM), the Company is in the process of expanding and expediting its product development and commercialization with a number of strategic alliances that will be announced over the next sixty days.
* * * * *
This news release contains forward-looking statements that involve a high degree of risk and uncertainty. Such statements include, but are not limited to, statements containing the words “believes,” “anticipates,” “expects,” “estimates,” and words of similar import. The Company’s actual results could differ materially from any forward-looking statements, which reflect management’s opinions only as of the date of this report, as a result of risks and uncertainties that exist in our operation, development efforts and business environment. The Company undertakes no obligation to revise or publicly release the results of any revisions to these forward-looking statements. You should carefully review the risk factors in other documents that the Company files from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. For additional information, visit the Biomoda web site at www.biomoda.com or call us at 505-821-0875.